TrialBMC cancer2024

Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinical trial.

Yinggang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.